丹芪通脉胶囊治疗冠心病心绞痛气虚血瘀型115例临床观察

Clinical efficacy of Danqi Tongmai capsules in treatment of angina pectoris with qi-deficiency and blood-stasis syndrome: a report of 115 cases

目的:观察丹芪通脉胶囊治疗冠心病心绞痛气虚血瘀型的临床疗效。方法:将215例冠心病心绞痛气虚血瘀型患者随机分成两组,其中对照组100例,给予常规西药治疗;治疗组115例,在常规西药治疗的基础上加用丹芪通脉胶囊治疗,疗程均为4周。观察治疗前后临床症状、血脂、肾功能、血流变、三大常规的变化以及有无不良反应。结果:治疗组疗效明显优于对照组,且能改善临床症状,改善心电图心肌缺血表现,纠正血脂代谢紊乱,降低血液黏稠度以及血清CRP、Hcy水平(P<0.05,P<0.01);肝肾功能和三大常规均无异常变化。结论:丹芪通脉胶囊治疗冠心病心绞痛气虚血瘀型有较好疗效,且安全可靠。

Objective： To investigate the clinical efficacy of Danqi Tongmai capsules in the treatment of angina pectoris（ AP） with qi- deficiency and blood- stasis syndrome. Methods： A total of 215 AP patients with qi- deficiency and blood- stasis syndrome were randomly divided into control group（ n = 100） that was treated with conventional Western medicine therapy and treatment group（ n = 115） that was treated with Danqi Tongmai capsules in addition to the conventional Western medicine therapy. The course of treatment was four weeks for both groups. The changes in clinical symptoms,blood lipids,renal function,hemorheology,and routine blood,urine and stool test results after treatment,as well as adverse events,were observed. Results： The treatment group had a significantly better clinical outcome than the control group,and it also showed significantly improved clinical symptoms,reduced myocardial ischemia on electrocardiogram,alleviated lipid metabolism disorder,and decreased blood viscosity and serum levels of C- reactive protein and homocysteine（ P〈0. 05; P〈0. 01）. The liver and renal function and routine blood,urine,and stool test results showed no abnormalities. Conclusion： Danqi Tongmai capsule has satisfactory clinical effect in the treatment of qi- deficiency and blood- stasis syndrome of CHD and AP with good safety and reliability.